#USA #Boston #XtalPi #IBS #KQTD-126

XtalPi's New Submission: KQTD-126 for Chronic Pain

XtalPi, a pioneering company in AI and robotics-driven drug discovery, has recently made headlines with its submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a novel treatment known as KQTD-126. This potential first-in-class drug is designed to target chronic intestinal pain, primarily associated with conditions like Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD).

Addressing an Unmet Need

Chronic abdominal pain is a significant challenge for millions across the globe. It's estimated that around 10%–15% of people live with IBS, and over 10 million are affected by IBD. Despite existing treatments that focus on controlling underlying inflammation, there remains a substantial gap for effective long-term pain relief. The global market for IBS and IBD therapeutic options is projected to reach an astonishing $52.6 billion by 2030, reflecting the urgent demand for innovative therapies.

Innovative Mechanism of Action

KQTD-126 is unique as it specifically targets the pan-tropomyosin receptor kinase (pan-TRK) family of receptors, which play a critical role in regulating nerve activity and amplifying pain signals in the gastrointestinal tract. Traditional systemic treatments often result in unacceptable neurological side effects due to their action within the central nervous system. In contrast, KQTD-126 is engineered to confine its activity to the gut, significantly reducing the risk of these adverse effects.

Achieving this targeted action required extensive exploration of the chemical landscape to balance potency and selectivity for its intended targets while limiting distribution. XtalPi utilized advanced AI models and a fleet of automated chemistry robots for a refined approach, employing a closed-loop process that integrates computational design, automated synthesis, empirical screening, and molecular refinement. This innovative pipeline allowed for the swift iteration across structural variations, ultimately achieving the desired efficacy in gut restriction alongside impactful target activity.

Preclinical Success and Next Steps

In rigorous preclinical studies, KQTD-126 demonstrated incredible potential, achieving pan-TRK inhibition at sub-nanomolar concentrations (IC₅₀ < 1 nM) and exhibiting high selectivity for its targets over other kinases. The drug also showed a favorable gut tissue-to-blood exposure ratio exceeding 1,000, asserting its profile as a locally acting treatment that promises sustained pain relief and a broader therapeutic window.

This IND submission marks a milestone for XtalPi, as KQTD-126 becomes the first asset from its proprietary pipeline to advance towards clinical testing. With a strong foundation in quantum physics, AI, and robotics, XtalPi aims to revolutionize drug discovery processes, focusing on delivering transformative therapies to patients worldwide.

A Vision for the Future

Founded in 2015 by physics experts from MIT, XtalPi has emerged as a leader in the field of drug discovery by leveraging cutting-edge technologies. The integration of first-principles calculations, AI, and automation allows XtalPi to provide intelligent and innovative solutions for a wide range of industries, including pharmaceuticals, materials science, agricultural technology, and more.

As KQTD-126 moves forward in its developmental journey, the industry watches closely. XtalPi's focus on addressing complex drug design challenges sets it apart in the landscape of biotechnology. With the potential for KQTD-126 to significantly improve the quality of life for individuals suffering from chronic intestinal pain, its success could mark a pivotal moment in pain management therapies.